3 results
• To assess the relative change in uptake of [18F]F-AraG in tumor lesions upon anti-PD-1 treatment• To assess the relationships between baseline tumor [18F]F-AraG uptake, change of tumor [18F]F-AraG uptake and tumor response to anti-PD-1 therapy
• To perform full kinetic modeling of [18F]F-AraG for the uptake in tumor lesions and healthy organs (e.g. spleen) by exploring different kinetic models and outcome measures as well as its test-retest (TRT) variability to guide the selection of an…
Primary objectives (Dose-escalation Phase):• To evaluate the safety and tolerability, describe the dose-limiting toxicities (DLTs), to determine the maximum tolerated dose (MTD), optimal biological dose (OBD), or highest protocol-defined dose (HPDD…